ROTE WILLIAM E.

Chief Research Officer sells 60,000 TVTX shares ($2.4M) at $40.10; reduces holdings by 37.2% to 101,443 shares

ROTE WILLIAM E., Chief Research Officer at Travere Therapeutics, sold 60,000 shares (60.0K shares) on 2025-12-24 at $40.10, reducing his holdings from 161,443 shares (161.4K shares) to 101,443 shares (101.4K shares) — a 37.2% reduction in his position. The sale occurred near the company's 52-week high of $40.28, with the stock up 62.7% over the prior 90 days and 9.8% over the prior 30 days. The company reported Revenue $164,859,000.00 ($164.9M) in its latest quarter and Net income $25,706,000.00 ($25.7M), alongside annual revenue growth of +60.6%; however, full-year net income was negative, indicating profitability occurred only in recent quarters despite headline fundamentals. The substantial reduction in the Chief Research Officer's direct stake warrants attention to whether this reflects confidence in longer-term execution or other considerations.